Integrated HTA
Each student is to submit an evaluation of a health technology. You need to assume that the technology is new and has not yet been publicly funded. The evaluation should address the following questions:
- Is pembrolizumab monotherapy for patients with PD-L1 positive, previously untreated, non-small cell lung cancer as, or more, safe and effective than chemotherapy? [30%]
- Develop PICO criteria for conducting a systematic review to assess the effectiveness and harm/safety of this health technology.
- Identify 3 pieces of evidence of good quality that address this question and narratively synthesise the findings from this evidence. The important patient-relevant outcomes described in your PICO criteria should form the basis of this synthesis.
- Broadly describe what you would do to model the results and determine the cost-effectiveness of pembrolizumab monotherapy relative to chemotherapy in patients that have PD-L1 positive, previously untreated non-small cell lung cancer. [30%]
- Use a structured approach or checklist as a guide for how to describe this model
- Identify and evaluate the likely applicability, extrapolation and transformation issues associated with applying the evidence identified to the economic model
- What are the ethical issues associated with testing for PD-L1 positivity and treating with pembrolizumab monotherapy? [20%]
- Use an ethics framework or checklist as a guide for how to do this ethical analysis
- Prepare a 2-page policy brief including a conclusion for your policy maker as to whether the health technology should be publicly funded. This should be included as the first section of your assignment. [20%]
The whole assignment should be no longer than 12 pages (6000 typed words single-spaced).
